Fig 1: HCFC1 promoted the proliferation and migration of HCC cells. (A) HCFC1 expression was elevated in HCC cell lines compared with normal liver cells. (B, C) The HCFC1 mRNA level was decreased in HepG2 (B) and Huh7 (C) cell lines after transfected shHCFC1. (D) Western blot assay validated the inhibitory effects of shHCFC1#1 in HepG2 and Huh7 cells. (E, F) CCK-8 assays detected the knockdown of HCFC1 on HepG2 (E) and Huh7 (F) cell viability. (G, H) Representative images and quantified analysis of transwell assays in HepG2 (G) and Huh7 (H) cells of shCtrl and shHCFC1 groups. (I, J) HepG2 (I) and Huh7 (J) cells transfected with shHCFC1 exhibited higher migration capacity in wound healing a than with shCtrl cells. (K- L) HepG2 (K) and Huh7 (L) cells transfected with shHCFC1 had a higher apoptosis rate than cells transfected with shCtrl. **P < 0.01, ***P < 0.001. ns: no statistically significant.
Fig 2: Differences in somatic mutations, TMB, and MSI Between HCFC1 high and low groups. (A) The mutation profiles exhibited the mutation difference of the top 15 genes in high and low HCFC1 expression groups. (B) High HCFC1 mRNA levels positively correlated with TMB, MATH, and MSI, whereas negatively correlated with tumor purity. (C) TMB (a), MSI (b), MATH (c), tumor purity (d), ploidy (e), HRD (f), Neoantigen (g), and LOH (h) values differ between high and low HCFC1 expression groups. *P < 0.05, **P < 0.01, ***P < 0.001.
Fig 3: HCFC1 expression of single-cell RNA sequencing analysis. (A) In eight datasets, the average expression value of HCFC1 mRNA in different types of cells. (B) HCFC1 mRNA expression in malignant cells, immune cells, and stromal cells in the LIHC_GSE125449_aPDL1aCTLA4 dataset. (C) HCFC1 expression in normal hepatocytes, malignant cells, epithelial cells, and monocytes/macrophages in the LIHC_GSE146409 dataset. (D) The distribution of various immune cells and corresponding HCFC1 mRNA expression levels in the LIHC_GSE140228_10X dataset.
Fig 4: HCFC1 protein levels correlated to the prognosis of patients in early-stage subgroups. (A-C) High HCFC1 protein expression predicted shorter OS time for patients in stage I/II (A), grade I/II (B), and median/well differentiation (C) subgroups. (D-F) High HCFC1 protein expression predicted shorter RFS time for patients in stage I/II (D), grade I/II (E), and median/well differentiation (F) subgroups. (G-I) Overall survival probability of patients with different HCFC1protein levels in small tumor size (less than 5cm, G), low AFP level (less than 400ng/ml, H), and Child-Pugh class A (I) subgroups. (J-L) survival probability of patients with different HCFC1protein levels in small tumor size (less than 5cm, J), low AFP level (less than 400ng/ml, L), and Child-Pugh class A (L) subgroups.
Fig 5: HCFC1 regulated the cell cycle of HCC cells. (A, B) The flow cytometry assays detect the cell cycle distribution of HepG2 (A) and Huh7 (B) cells. (C, D) Western blots images (C) and statistical analysis (D) of the protein expression of cell cycle-related markers in transfected HCC cells. *P < 0.05, **P < 0.01, ***P < 0.001.
Supplier Page from Abcam for Anti-HCF-1 / Host Cell Factor C1 antibody - N-terminal